应用美降之和立平脂进行降脂治疗对冠心病康复的影响  

Clinical Observation of Lovastatin and Lipanthyl in Treatment of Patients With Primary Hyperlipidemia

作　　者：杨菊贤[1] 吴士尧[1] 盛净[1] 黄震华[1] 吕利雄[1] 

机构地区：[1]上海第二医科大学附属第九人民医院

出　　处：《中国心血管康复医学》1995年第1期4-7,共4页

摘　　要：美降之(Lovastatin)是胆固醇合成酶系中限速酶甲基羟戊二酰辅酶A(HMG·COA)还原酶的竞争性抑制剂，是目前我国用于降低血清胆固醇的有效药物之一。立平脂(Lipanthyl)也具有HMG·COA还原酶的竞争抑制作用，也是临床应用的第一线药物。我院近年来先后应用该两种药物降脂治疗，现将规察结果报道如下。This paper reports the efficacy of Lovastatin and Lipanthyl to patients with primary hyperlipidemia in 60 cases.The results showed that,8 weeks after taking Lovastatin,the percentage of the patients whose serum Chlesterol(Ch) and Triglyceride(Tg) level dropped were 86. 87% and 53. 84% respectively. And the average dropping ratio were Ch 20. 62% .LDL-C 9. 78% .APO-B 10. 74% and Ch/HDL 29. 70% ; The average elevation ratio were HDL-C 11. 91% ,APO-A 12. 57% and APO-A/APO-B 24. 51%. There was a significent dropping of serum Tg level 8 weeks after taking Lipanthyl ,and its total efficacy was 84. 61%,however,except for Tg ,other parameters of Lipanthyl had less efficacy than Lovastatin.

关 键 词：美降之 立平脂 降脂治疗 冠心病 身体康复 竞争性抑制剂 

分 类 号：R541.4[医药卫生—心血管疾病] R972[医药卫生—内科学]